5-fluorouracil cardiotoxicity is a rare, dose and schedule-dependent adverse event: A prospective study

Journal of B.U.ON.

Volumn 10, Issue 2, 2005, Pages 205-211

  Tsavaris, Nickolas ^a   Kosmas, C ^a   Vadiaka, M ^a   Skopelitis, E ^a   Kopteridis, P ^a   Pamouki, S ^a   Efremidis, M ^a   Kasparian, H ^a   Moisakis, I ^a   Sakelariou, D ^a   Koufos, C ^a  

^a UNIVERSITY OF ATHENS   (Greece)

Author keywords

5 fluorouracil; Cancer; Cardiotoxicity; Chemotherapy; Toxicity

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CISPLATIN; CREATINE KINASE; CREATINE KINASE MB; FLUOROURACIL; FOLINIC ACID; HEART ENZYME; LACTATE DEHYDROGENASE; MITOMYCIN C; NITRATE;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; CARDIOTOXICITY; CLINICAL ARTICLE; CLINICAL FEATURE; COLORECTAL CANCER; CORONARY ARTERY SPASM; DIAPHORESIS; DOSE RESPONSE; DRUG INFUSION; ELECTROCARDIOGRAM; FEMALE; HEAD AND NECK CANCER; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART MUSCLE CONDUCTION DISTURBANCE; HEART MUSCLE ISCHEMIA; HEART PALPITATION; HEART VENTRICLE EXTRASYSTOLE; HEART VENTRICLE TACHYCARDIA; HUMAN; MALAISE; MALE; MALIGNANT NEOPLASTIC DISEASE; NECK PAIN; PARESTHESIA; PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA; PROSPECTIVE STUDY; RARE DISEASE; RISK FACTOR; SIDE EFFECT; SINUS TACHYCARDIA; SYNCOPE; THORAX PAIN; UNCONSCIOUSNESS;

EID: 24944440623     PISSN: 11070625     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Blum RH, Carter SK. Adriamycin: A new anticancer drug with significant clinical activicy. Ann Intern Med 1974; 80: 249-259.
2. Von Hoff DD, Rozencweig M, Layard M, Slavik M, Mugglia FM. Daunomycin induced cardiotoxicity in children and adults: A review of 110 cases. Am J Med 1977; 62: 200-208.
3. Moertel CG, Reitermeier RJ. Experience with 5-fluoruracil in the palliative management of advanced carcinoma of the gastrointestinal track. Staff meeting of the Mayo Clinic 1962; 37: 520-529.
4. Pollage A, Holt S, Ludgate S, Lannglands AO. Fluorouracil cardiotoxicity. Br Med J 1978; 1: 547.
5. Soukop M, McVie JG, Calman KC. Fluorouracil cardiotoxicity. Br Med J 1978; 1: 1422.
6. Villani F, Guindani A, Pagnoni A. 5-fluorouracil cardiotoxicity. Tumori 1979; 65: 487-495.
7. Roth A, Kolaric K, Popovic S. Cardiotoxicity of 5-fluorouracil (NSC 1993). Cancer Chemother Rep 1975; 59: 1051-1052.
8. Gavenau T, Bauzet P, Marneffe H, Viars P. Traubles cardiovasculaires an cours d'infusions d'anti-mitociques a fortes doses: 30 observacions cliniques. Anesch Anal Rean 1969; 26: 311-327.
9. Grem JL. 5-Fluoropyrimidines. In: Chabner BA, Longo DL (eds): Cancer chemotherapy and biotherapy: principles and practice (2nd edn). Philadelphia, Lippincott-Raven, 1996: p149.
10. Mosseri M, Fingert HJ, Varticovoski L et al. In vitro evidence that myocardial ischemia resulting from 5-fluorouracil chemotherapy is due to protein kinase C-mediated vasoconstriction of vascular smooth muscle. Cancer Res 1993; 53:3028-3033.
11. De Forni M, Malet-Martino MC, Jaillais P et al. Cardiotoxicity of high-dose continuous infusion fluorouracil: a prospective clinical study. J Clin Oncol 1992; 10: 1795-1801.
12. Akhtar S, Salim K, Bano Z. Symptomatic cardiotoxicity with high-dose 5-fluorouracil infusion: a prospective study. Oncology 1993; 50: 441-444.
13. Meyer C, Anton Calis K, Burke L et al. Symptomatic cardiotoxicity associated with 5-fluorouracil. Pharmacotherapy 1997; 17: 729-736.
14. Labianca R, Beretta G, Clerici M et al. Cardiac toxicity of 5-fluorouracil: a study on 1083 patients. Tumori 1982; 68: 505-510.
15. Grandi A, Pinotti G, Morandi E et al. Noninvasive evaluation of cardiotoxicity of 5-fluorouracil and low doses of folinic acid: a one-year follow-up study. Ann Oncol 1997; 8: 705-708.
16. Rezkalla S, Kloner R, Ensley M et al. Continuous ambulatory ECG monitoring during fluorouracil therapy: a prospective study. J Clin Oncol 1989; 7: 509-514.
17. Freeman N, Costanza M. 5-Fluorouracil-associated cardiotoxicity. Cancer 1988; 61: 36-45.
18. Porta C, Moroni M, Ferrari S, Nastasi G. Endothelin-1 and 5-fluorouracil induced cardiotoxicity. Neoplasma 1998; 45: 81-82.
19. Levillain R. Experimental myocarditis; anatomical study of 210 rat hearts after ingestion of 5-fluorouracil. Comptes rendues des seances de la Societie de Biologie et de ses Filiales 1972; 166: 310-312.
20. Matsubara I, Kamiya J, Imai S. Cardiotoxic effects of 5-fluorouracil in the guinea pig. Jpn J Pharmacol 1980; 30: 871-879.
21. Stevenson D, Mikhailidis D, Gillett D. Cardiotoxicity of 5-fluorouracil. Lancet 1977; 2: 406-407.
22. Lemaire L, Malet-Martino M, Longo S et al. Fluoroacetate as cardiotoxic impurity in fluorouracil (Roche). Lancet 1991; 337: 560.
23. Cwikiel M, Eskilsson J, Albertsson M, Stavenow L. The influence of 5-fluorouracil and methotrexate on vascular endothelium. An experimental study using endothelial cells in the culture. Ann Oncol 1996; 7: 731-737.
24. Cwikiel M, Albertsson M, Zhang B et al. The influence of 5-fluorouracil on the endothelium in small arteries. A scanning and transmission electron microscopic study in rabbits. Scan Micros 1995; 9: 561-576.
25. Cwikiel M, Eskilsson J, Wieslander JB et al. The appearance of endothelium in small arteries after treatment with 5-fluorouracil. An electron microscopic study of late effects in rabbits. Scan Micros 1996; 10: 187-192.
26. Sasson Z, Morgan C, Wang B et al. 5-Fluorouracil related toxic myocarditis: Case reports and pathological confirmation. Can J Cardiol 1994; 10: 861-864.